Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Interleukin-15 (IL-15) Strongly Correlates with Increasing HIV-1 Viremia and Markers of Inflammation.

Swaminathan S, Qiu J, Rupert AW, Hu Z, Higgins J, Dewar RL, Stevens R, Rehm CA, Metcalf JA, Sherman BT, Baseler MW, Lane HC, Imamichi T.

PLoS One. 2016 Nov 23;11(11):e0167091. doi: 10.1371/journal.pone.0167091. eCollection 2016.

2.

The effects of storage temperature on PBMC gene expression.

Yang J, Diaz N, Adelsberger J, Zhou X, Stevens R, Rupert A, Metcalf JA, Baseler M, Barbon C, Imamichi T, Lempicki R, Cosentino LM.

BMC Immunol. 2016 Mar 15;17:6. doi: 10.1186/s12865-016-0144-1.

3.

Circulating CXCR5⁺CD4⁺ T Follicular-Like Helper Cell and Memory B Cell Responses to Human Papillomavirus Vaccines.

Matsui K, Adelsberger JW, Kemp TJ, Baseler MW, Ledgerwood JE, Pinto LA.

PLoS One. 2015 Sep 2;10(9):e0137195. doi: 10.1371/journal.pone.0137195. eCollection 2015.

4.

Plasma interleukin-27 (IL-27) levels are not modulated in patients with chronic HIV-1 infection.

Swaminathan S, Hu Z, Rupert AW, Higgins JM, Dewar RL, Stevens R, Chen Q, Rehm CA, Metcalf JA, Baseler MW, Lane HC, Imamichi T.

PLoS One. 2014 Jun 4;9(6):e98989. doi: 10.1371/journal.pone.0098989. eCollection 2014.

5.

Interleukin-2 inhibits HIV-1 replication in some human T cell lymphotrophic virus-1-infected cell lines via the induction and incorporation of APOBEC3G into the virion.

Oguariri RM, Dai L, Adelsberger JW, Rupert A, Stevens R, Yang J, Huang D, Lempicki RA, Zhou M, Baseler MW, Lane HC, Imamichi T.

J Biol Chem. 2013 Jun 14;288(24):17812-22. doi: 10.1074/jbc.M113.468975. Epub 2013 May 2.

6.

Interleukin-27 treated human macrophages induce the expression of novel microRNAs which may mediate anti-viral properties.

Swaminathan S, Hu X, Zheng X, Kriga Y, Shetty J, Zhao Y, Stephens R, Tran B, Baseler MW, Yang J, Lempicki RA, Huang D, Lane HC, Imamichi T.

Biochem Biophys Res Commun. 2013 May 3;434(2):228-34. doi: 10.1016/j.bbrc.2013.03.046. Epub 2013 Mar 25.

7.

The CD8+ HLA-DR+ T cells expanded in HIV-1 infection are qualitatively identical to those from healthy controls.

Imamichi H, Lempicki RA, Adelsberger JW, Hasley RB, Rosenberg A, Roby G, Rehm CA, Nelson A, Krishnan S, Pavlick M, Woods CJ, Baseler MW, Lane HC.

Eur J Immunol. 2012 Oct;42(10):2608-20. doi: 10.1002/eji.201142046. Epub 2012 Aug 6.

8.

DAVID-WS: a stateful web service to facilitate gene/protein list analysis.

Jiao X, Sherman BT, Huang da W, Stephens R, Baseler MW, Lane HC, Lempicki RA.

Bioinformatics. 2012 Jul 1;28(13):1805-6. doi: 10.1093/bioinformatics/bts251. Epub 2012 Apr 27.

9.

Cutting edge: Ku70 is a novel cytosolic DNA sensor that induces type III rather than type I IFN.

Zhang X, Brann TW, Zhou M, Yang J, Oguariri RM, Lidie KB, Imamichi H, Huang DW, Lempicki RA, Baseler MW, Veenstra TD, Young HA, Lane HC, Imamichi T.

J Immunol. 2011 Apr 15;186(8):4541-5. doi: 10.4049/jimmunol.1003389. Epub 2011 Mar 11.

10.

CD4 and CD8 T cell immune activation during chronic HIV infection: roles of homeostasis, HIV, type I IFN, and IL-7.

Catalfamo M, Wilhelm C, Tcheung L, Proschan M, Friesen T, Park JH, Adelsberger J, Baseler M, Maldarelli F, Davey R, Roby G, Rehm C, Lane C.

J Immunol. 2011 Feb 15;186(4):2106-16. doi: 10.4049/jimmunol.1002000. Epub 2011 Jan 21.

11.

Evaluation of the effect of pyrimethamine, an anti-malarial drug, on HIV-1 replication.

Oguariri RM, Adelsberger JW, Baseler MW, Imamichi T.

Virus Res. 2010 Nov;153(2):269-76. doi: 10.1016/j.virusres.2010.08.018. Epub 2010 Aug 26.

12.

Evaluation of the Performance of the Sysmex XT-2000i Hematology Analyzer With Whole Bloods Stored at Room Temperature.

Hill VL, Simpson VZ, Higgins JM, Hu Z, Stevens RA, Metcalf JA, Baseler M.

Lab Med. 2009 Dec;40(12):709-718. No abstract available.

13.

Application of a flow cytometric cytotoxicity assay for monitoring cancer vaccine trials.

Zaritskaya L, Shafer-Weaver KA, Gregory MK, Strobl SL, Baseler M, Malyguine A.

J Immunother. 2009 Feb-Mar;32(2):186-94. doi: 10.1097/CJI.0b013e318197b1b2.

PMID:
19238018
14.

HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells.

Catalfamo M, Di Mascio M, Hu Z, Srinivasula S, Thaker V, Adelsberger J, Rupert A, Baseler M, Tagaya Y, Roby G, Rehm C, Follmann D, Lane HC.

Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19851-6. doi: 10.1073/pnas.0810032105. Epub 2008 Dec 5.

15.

DAVID gene ID conversion tool.

Huang da W, Sherman BT, Stephens R, Baseler MW, Lane HC, Lempicki RA.

Bioinformation. 2008 Jul 30;2(10):428-30.

16.

Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors.

Zonios DI, Falloon J, Bennett JE, Shaw PA, Chaitt D, Baseler MW, Adelsberger JW, Metcalf JA, Polis MA, Kovacs SB, Kovacs JA, Davey RT, Lane HC, Masur H, Sereti I.

Blood. 2008 Jul 15;112(2):287-94. doi: 10.1182/blood-2007-12-127878. Epub 2008 May 2. Erratum in: Blood. 2014 Jul 17;124(3):463. Kovacs, Stephen J [corrected to Kovacs, Stephen B].

17.

Effects of delays in peripheral blood processing, including cryopreservation, on detection of CD31 expression on naive CD4 T cells.

Higgins J, Metcalf JA, Stevens RA, Baseler M, Proschan M, Lane HC, Sereti I.

Clin Vaccine Immunol. 2008 Jul;15(7):1141-3. doi: 10.1128/CVI.00430-07. Epub 2008 Apr 30.

18.

IL-27, a novel anti-HIV cytokine, activates multiple interferon-inducible genes in macrophages.

Imamichi T, Yang J, Huang DW, Brann TW, Fullmer BA, Adelsberger JW, Lempicki RA, Baseler MW, Lane HC.

AIDS. 2008 Jan 2;22(1):39-45.

PMID:
18090390
19.

DAVID Knowledgebase: a gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis.

Sherman BT, Huang da W, Tan Q, Guo Y, Bour S, Liu D, Stephens R, Baseler MW, Lane HC, Lempicki RA.

BMC Bioinformatics. 2007 Nov 2;8:426.

20.

The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists.

Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, Stephens R, Baseler MW, Lane HC, Lempicki RA.

Genome Biol. 2007;8(9):R183.

21.

Evaluation of a single-platform technology for lymphocyte immunophenotyping.

Higgins J, Hill V, Lau K, Simpson V, Roayaei J, Klabansky R, Stevens RA, Metcalf JA, Baseler M.

Clin Vaccine Immunol. 2007 Oct;14(10):1342-8. Epub 2007 Aug 29.

22.

New approaches for monitoring CTL activity in clinical trials.

Malyguine A, Strobl S, Zaritskaya L, Baseler M, Shafer-Weaver K.

Adv Exp Med Biol. 2007;601:273-84. Review.

PMID:
17713015
23.

Detection of KIR3DS1 on the cell surface of peripheral blood NK cells facilitates identification of a novel null allele and assessment of KIR3DS1 expression during HIV-1 infection.

Pascal V, Yamada E, Martin MP, Alter G, Altfeld M, Metcalf JA, Baseler MW, Adelsberger JW, Carrington M, Anderson SK, McVicar DW.

J Immunol. 2007 Aug 1;179(3):1625-33.

24.

DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists.

Huang DW, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, Guo Y, Stephens R, Baseler MW, Lane HC, Lempicki RA.

Nucleic Acids Res. 2007 Jul;35(Web Server issue):W169-75. Epub 2007 Jun 18.

25.

Application of the granzyme B ELISPOT assay for monitoring cancer vaccine trials.

Shafer-Weaver K, Rosenberg S, Strobl S, Gregory Alvord W, Baseler M, Malyguine A.

J Immunother. 2006 May-Jun;29(3):328-35.

PMID:
16699376
26.

Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals.

Morgan RA, Walker R, Carter CS, Natarajan V, Tavel JA, Bechtel C, Herpin B, Muul L, Zheng Z, Jagannatha S, Bunnell BA, Fellowes V, Metcalf JA, Stevens R, Baseler M, Leitman SF, Read EJ, Blaese RM, Lane HC.

Hum Gene Ther. 2005 Sep;16(9):1065-74.

PMID:
16149905
27.

Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients.

Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Sereti I, Sachau W, Kelly G, Metcalf JA, Davey RT Jr, Falloon J, Polis MA, Tavel J, Stevens R, Lambert L, Hosack DA, Bosche M, Issaq HJ, Fox SD, Leitman S, Baseler MW, Masur H, Di Mascio M, Dimitrov DS, Lane HC.

J Clin Invest. 2005 Aug;115(8):2139-48. Epub 2005 Jul 14.

28.

A novel flow cytometric assay for evaluating cell-mediated cytotoxicity.

Burkett MW, Shafer-Weaver KA, Strobl S, Baseler M, Malyguine A.

J Immunother. 2005 Jul-Aug;28(4):396-402.

PMID:
16000959
29.

Effects of lymphocyte isolation and timing of processing on detection of CD127 expression on T cells in human immunodeficiency virus-infected patients.

Higgins J, Metcalf JA, Stevens RA, Baseler M, Nason MC, Lane HC, Sereti I.

Clin Diagn Lab Immunol. 2005 Jan;12(1):228-30.

30.

Fixation and cryopreservation of whole blood and isolated mononuclear cells: Influence of different procedures on lymphocyte subset analysis by flow cytometry.

Pinto LA, Trivett MT, Wallace D, Higgins J, Baseler M, Terabe M, Belyakov IM, Berzofsky JA, Hildesheim A.

Cytometry B Clin Cytom. 2005 Jan;63(1):47-55.

31.

Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay.

Shafer-Weaver KA, Sayers T, Kuhns DB, Strobl SL, Burkett MW, Baseler M, Malyguine A.

J Transl Med. 2004 Sep 20;2(1):31.

32.

A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection.

Dybul M, Nies-Kraske E, Dewar R, Maldarelli F, Hallahan CW, Daucher M, Piscitelli SC, Ehler L, Weigand A, Palmer S, Metcalf JA, Davey RT, Rock Kress DM, Powers A, Beck I, Frenkel L, Baseler M, Coffin J, Fauci AS.

J Infect Dis. 2004 Jun 1;189(11):1974-82. Epub 2004 May 10.

PMID:
15143462
33.

A modified human ELISPOT assay to detect specific responses to primary tumor cell targets.

Malyguine A, Strobl SL, Shafer-Weaver KA, Ulderich T, Troke A, Baseler M, Kwak LW, Neelapu SS.

J Transl Med. 2004 Mar 29;2(1):9.

34.

The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity.

Shafer-Weaver K, Sayers T, Strobl S, Derby E, Ulderich T, Baseler M, Malyguine A.

J Transl Med. 2003 Dec 29;1(1):14.

35.

A comparison of microLC/electrospray ionization-MS and GC/MS for the measurement of stable isotope enrichment from a [2H2]-glucose metabolic probe in T-cell genomic DNA.

Fox SD, Lempicki RA, Hosack DA, Baseler MW, Kovacs JA, Lane HC, Veenstra TD, Issaq HJ.

Anal Chem. 2003 Dec 1;75(23):6517-22.

PMID:
14640722
36.

A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus.

Tavel JA, Sereti I, Walker RE, Hahn B, Kovacs JA, Jagannatha S, Davey RT Jr, Falloon J, Polis MA, Masur H, Metcalf JA, Stevens R, Rupert A, Baseler M, Lane HC.

J Infect Dis. 2003 Aug 15;188(4):531-6. Epub 2003 Jul 31.

PMID:
12898439
37.

Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.

Pinto LA, Edwards J, Castle PE, Harro CD, Lowy DR, Schiller JT, Wallace D, Kopp W, Adelsberger JW, Baseler MW, Berzofsky JA, Hildesheim A.

J Infect Dis. 2003 Jul 15;188(2):327-38. Epub 2003 Jul 9.

PMID:
12854090
38.

Actinomycin D induces high-level resistance to thymidine analogs in replication of human immunodeficiency virus type 1 by interfering with host cell thymidine kinase expression.

Imamichi T, Murphy MA, Adelsberger JW, Yang J, Watkins CM, Berg SC, Baseler MW, Lempicki RA, Guo J, Levin JG, Lane HC.

J Virol. 2003 Jan;77(2):1011-20.

39.

Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells.

Sereti I, Martinez-Wilson H, Metcalf JA, Baseler MW, Hallahan CW, Hahn B, Hengel RL, Davey RT, Kovacs JA, Lane HC.

Blood. 2002 Sep 15;100(6):2159-67.

40.

Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection.

Natarajan V, Lempicki RA, Sereti I, Badralmaa Y, Adelsberger JW, Metcalf JA, Prieto DA, Stevens R, Baseler MW, Kovacs JA, Lane HC.

Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10712-7. Epub 2002 Jul 29.

41.

Study of diverse mechanisms of cell-mediated cytotoxicity in gene-targeted mice using flow cytometric cytotoxicity assay.

Malyguine A, Derby E, Brooks A, Reddy V, Baseler M, Sayers T.

Immunol Lett. 2002 Aug 1;83(1):55-9.

PMID:
12057855
42.

Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV.

Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Herpin B, Metcalf JA, Sereti I, Polis MA, Davey RT, Tavel J, Falloon J, Stevens R, Lambert L, Dewar R, Schwartzentruber DJ, Anver MR, Baseler MW, Masur H, Dimitrov DS, Lane HC.

J Exp Med. 2001 Dec 17;194(12):1731-41.

43.

Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters.

Dybul M, Chun TW, Yoder C, Hidalgo B, Belson M, Hertogs K, Larder B, Dewar RL, Fox CH, Hallahan CW, Justement JS, Migueles SA, Metcalf JA, Davey RT, Daucher M, Pandya P, Baseler M, Ward DJ, Fauci AS.

Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15161-6. Epub 2001 Dec 4.

44.

Evidence for increased T cell turnover and decreased thymic output in HIV infection.

Douek DC, Betts MR, Hill BJ, Little SJ, Lempicki R, Metcalf JA, Casazza J, Yoder C, Adelsberger JW, Stevens RA, Baseler MW, Keiser P, Richman DD, Davey RT, Koup RA.

J Immunol. 2001 Dec 1;167(11):6663-8.

45.

CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients.

Sereti I, Herpin B, Metcalf JA, Stevens R, Baseler MW, Hallahan CW, Kovacs JA, Davey RT, Lane HC.

AIDS. 2001 Sep 28;15(14):1765-75.

PMID:
11579237
46.

Flow cytometric assay for the simultaneous analysis of cell-mediated cytotoxicity and effector cell phenotype.

Derby E, Reddy V, Baseler M, Malyguine A.

Biotechniques. 2001 Sep;31(3):660, 664-5. No abstract available.

47.

HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals.

Moir S, Malaspina A, Ogwaro KM, Donoghue ET, Hallahan CW, Ehler LA, Liu S, Adelsberger J, Lapointe R, Hwu P, Baseler M, Orenstein JM, Chun TW, Mican JA, Fauci AS.

Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10362-7. Epub 2001 Aug 14.

48.

Three-color flow cytometric assay for the study of the mechanisms of cell-mediated cytotoxicity.

Derby E, Reddy V, Kopp W, Nelson E, Baseler M, Sayers T, Malyguine A.

Immunol Lett. 2001 Aug 1;78(1):35-9.

PMID:
11470149
49.

Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy.

Kovacs JA, Vogel S, Metcalf JA, Baseler M, Stevens R, Adelsberger J, Lempicki R, Hengel RL, Sereti I, Lambert L, Dewar RL, Davey RT Jr, Walker RE, Falloon J, Polis MA, Masur H, Lane HC.

Eur J Immunol. 2001 May;31(5):1351-60.

50.

Correlation of human CD56+ cell cytotoxicity and IFN-gamma production.

Derby EG, Reddy V, Nelson EL, Kopp WC, Baseler MW, Dawson JR, Malyguine AM.

Cytokine. 2001 Jan 21;13(2):85-90.

PMID:
11145847

Supplemental Content

Loading ...
Support Center